KERATO Celebrates 5-Year Anniversary with New Miami Location and Over 1000 Successful Cases

August 8, 2024 12:00 PM

NEW YORK, NY and MIAMI, FL / ACCESSWIRE / August 8, 2024 / Imagine a world where changing your eye color is not just a dream but a safe and seamless reality. This vision has been materialized through the innovative efforts of KERATO, a pioneer in the field of cosmetic keratopigmentation. As KERATO celebrates its 5-year anniversary, it proudly announces the opening of a new location in Miami, further expanding its reach and bringing its...

Read more

Truss Health and KIMS Hospital Announce Strategic Partnership to Revolutionize Postoperative Care using AI-Powered Sensor Fusion Technology

August 8, 2024 11:03 AM

Truss Health, a leading innovator in healthcare technology, is excited to announce a strategic partnership with KIMS Hospital group , one of the largest corporate healthcare groups in India. This collaboration aims to significantly enhance postoperative care and infection control by integrating Truss Health's advanced AI-driven sensor fusion technology with KIMS Hospital's clinical expertise.From left to right: Dr. Abhinay Bollineni, CEO KIMS...

Read more

Electromedical Provides Update to Shareholders

August 8, 2024 11:00 AM

Electromedical (EMED), a Leader in Bioelectronic Medical Devices, Updates Shareholders on Recent Achievements and Strategic AdvancementsSCOTTSDALE, AZ / ACCESSWIRE / August 8, 2024 / Electromedical (OTC PINK:EMED), a leading innovator in bioelectronic medical devices, is pleased to provide an update to its shareholders, highlighting significant recent achievements and strategic advancements. EMED Logo Sales Growth: 17% increase in revenue in...

Read more

My Quest Story - Jamie Croft

August 8, 2024 10:45 AM

NORTHAMPTON, MA / ACCESSWIRE / August 8, 2024 / Quest Diagnostics National Logistics Day was June 28th. Join us in celebrating our logistics professionals who play a vital role in ensuring each specimen is treated like a life and delivered to our labs across the country. Thank you for your hard work and dedication to our purpose of working together to create a healthier world, one life at a time.---I had always wanted to do something in the...

Read more

Closing the HIV Diagnosis Gap in Germany with Gilead Sciences

August 8, 2024 10:15 AM

NORTHAMPTON, MA / ACCESSWIRE / August 8, 2024 / Gilead SciencesAs a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals. Yet the country acknowledges it still has significant work to do to close the gaps in diagnosis that still exist, mainly in its rural and migrant communities.Early diagnosis is essential to help end the HIV epidemic, which is...

Read more

Superhuman 2 "Rebirth" Introducing Nikki

August 8, 2024 8:30 AM

Frequency Exchange Corp. ("Frequency Exchange" or the "Company") (TSXV:FREQ) is excited to announce that its wholly-owned subsidiary, FREmedica Technologies Inc. ("FREmedica"), is partnering with Caroline Cory, an Award Winning Executive Producer known for her documentaries that air on Netflix and Prime Video. Caroline has millions of viewers and continues to produce films of interest, particularly in the world of frequencies.In 2020, an...

Read more

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

August 8, 2024 8:05 AM

SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update."After the successful completion of our APVO436 dose expansion trial, where we saw a 91%...

Read more

Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance

August 8, 2024 8:00 AM

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's mBôs TKA System. The application was submitted on July 19, 2024, and passed the FDA Administrative Review. An FDA decision is expected...

Read more

Hear AtLast and A.C.T. Investment Group Sign Agreement for Purchase of Income Properties In North America

August 8, 2024 8:00 AM

MIAMI, FL / ACCESSWIRE / August 8, 2024 / Hear AtLast (OTC PINK:HRAL) is excited to announce its new venture with A.C.T. Investments to engage to purchase income properties across North America. This will be an opportune time to invest in residential and proposed land development of high rise residential.A.C.T. Investments is a group of investors who are developing and purchasing homes for low income families surrounding Rochester. HRAL and...

Read more

Registration is Now Open for Tribe Public’s Webinar Event "Diabetes Care Innovator Modular Medical Takes Next Steps" Featuring Modular Medical CEO on Friday, August 9, 2024

August 8, 2024 8:00 AM

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032Discover how Modular Medical is accelerating the development of technology to empower the whole diabetes community with MODD1Meet with Modular Medical CEO Jeb BesserSAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD)...

Read more

Xtant Medical Announces $5.0 Million Private Placement

August 8, 2024 7:20 AM

Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting...

Read more

Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

August 8, 2024 7:10 AM

Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call...

Read more

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

August 8, 2024 7:05 AM

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.Second Quarter 2024 Financial HighlightsRevenue of $29.9 million, up 48%, compared to the prior year quarterGross margin of 62.1%, up 50 basis points, compared to the prior year quarterNet loss of $3.9...

Read more

Bionoid Pharma, Inc. Acquires AI Maverick Intel

August 8, 2024 7:00 AM

Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) announces the signing of a definitive agreement with Stronghold Media Group Corp. ("Stronghold") to acquire the intellectual property rights of AI Maverick Intel, a cutting-edge technology set to revolutionize customer acquisition by enabling companies to find, engage, nurture, and acquire their ideal audiences at high velocity and automated scale. Revolutionizing Audience Engagement with AI...

Read more

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

August 8, 2024 6:30 AM

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program and strategy in this letter to investors.NanoViricides is developing a unique direct-acting antiviral drug that mimics the host cell and thereby is designed to disable the virus particle from infecting the cell. Our first clinical stage drug, NV-387 is designed to mimic...

Read more

SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers

August 8, 2024 4:30 AM

Diagnostics company SphingoTec GmbH ("SphingoTec") announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its products. This includes supporting market development, out-licensing activities, and close collaboration with licensees. SphingoTec aims for global expansion, including entry into the US market. The lead...

Read more

NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

August 8, 2024 2:40 AM

NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based DNA vaccine designed to target patient-specific tumor neoantigens. This important and promising collaboration aims to enhance the production of personalized cancer treatments by leveraging the biotechnology strengths of both companies.Advancing Personalized Cancer TreatmentNEC Bio Therapeutics, a...

Read more

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

August 8, 2024 1:50 AM

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify...

Read more

Kuros Biosciences Reports First Half of 2024 Results

August 8, 2024 1:30 AM

Financial HighlightsDirect MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023Total Kuros Medical Devices segment sales increased 148% to CHF 31.8 million from CHF 12.9 millionKuros Medical Devices segment EBITDA increased 287% to CHF 8.6 million in H1 2024 compared to CHF 2.2 million in H1 2023, representing an EBITDA margin of...

Read more

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024

August 7, 2024 4:05 PM

Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024.Second Quarter HighlightsNet revenues of $182.4 million for the second quarterGAAP net income of $37.9 million, or $0.73 per share, for the second quarterAdjusted non-GAAP net...

Read more